[ Skip to main content ]

Articles

Media release
Sep 30
2016

Submissions on e-cigs and drug utensils

30 Sep 2016

In September the Drug Foundation made submissions on two Ministry of Health consultation documents: Policy Options for the Regulation of Electronic Cigarettes and Review of Drug Utensils Regulation.

Media release
Aug 15
2016

Majority backs cannabis law change

15 Aug 2016

A majority of the public favours a change to the legal status of cannabis according to a new poll commissioned by the NZ Drug Foundation.

News

Review of Drug Utensils Regulation - submit now!

10 Aug 2016

The Ministry of Health has recently taken an important initial step in addressing one of five priority areas of the National Drug Policy (NDP) by releasing a discussion document on a review of drug utensils regulation.

Article

Q&A: Gilbert Taurua

1 Aug 2016

In May 2016, Gilbert Taurua joined the Drug Foundation to lead a new area of work promoting better drug laws for Māori.

Article

Guest editorial: Complexities and challenges - NZ's Drug Harm Index 2016

1 Aug 2016

Drug harm indexes are complicated methodological tools used to analyse and measure harms resulting from the complicated and complex practice that is drug use.

Article

Viewpoints: A price too far?

1 Aug 2016

In this edition, Viewpoints looks at whether tax increases are an effective public heath tool to reduce tobacco consumption and finds the answer is yes and no – it depends on your perspective.

Article

Veronal: who remembers veronal?

1 Aug 2016

Redmer Yska delves into the dramatic side effects of a once-popular barbiturate.

Article

Breaking the ice- how we will get through Australia's methamphetamine crisis

1 Aug 2016

Worried that parents were getting misinformation about out-of-control methamphetamine use in Australia, Matt Noffs wrote a book to reassure people not to panic.

Article

Portugal: putting health and welfare at the centre of drug policy

1 Aug 2016

With solid evidence showing punitive approaches to drugs do not work, the question that arises is what to do instead? In this first instalment of a Matters of Substance series on innovative drug policies in different countries, we look at P